WO2007133112A1 - Dérivés de noscapine (et variantes), bibliothèques combinatoire et focalisée, composition pharmaceutique et procédés de fabrication (variantes) et d'utilisation - Google Patents

Dérivés de noscapine (et variantes), bibliothèques combinatoire et focalisée, composition pharmaceutique et procédés de fabrication (variantes) et d'utilisation Download PDF

Info

Publication number
WO2007133112A1
WO2007133112A1 PCT/RU2007/000138 RU2007000138W WO2007133112A1 WO 2007133112 A1 WO2007133112 A1 WO 2007133112A1 RU 2007000138 W RU2007000138 W RU 2007000138W WO 2007133112 A1 WO2007133112 A1 WO 2007133112A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
tetrahydro
methoxy
dimethoxy
dioxolo
Prior art date
Application number
PCT/RU2007/000138
Other languages
English (en)
Russian (ru)
Inventor
Alexander Vasilievich Ivashchenko
Volodymyr Mikhailovich Kysil
Alexander Viktorovich Khvat
Sergey Viktorovich Malyarchuk
Ilya Matusovich Okun
Sergey Yevgenievich Tkachenko
Alexander Sergeevich Kyselev
Original Assignee
Ivashchenko, Andrey Alexandrovich
Chemdiv, Ink
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivashchenko, Andrey Alexandrovich, Chemdiv, Ink filed Critical Ivashchenko, Andrey Alexandrovich
Publication of WO2007133112A1 publication Critical patent/WO2007133112A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Noscapine derivatives (options), combinatorial and focused libraries, pharmaceutical composition, methods for their preparation (options) and applications
  • This invention relates to new derivatives of the natural alkaloid of noscapine or (S, R) -6,7-dimethoxy-3- (5,6,7,8-tetrahydro-4-methoxy-6-methyl-l, 3-dioxol [4 , 5-g] isoxinolin-5-yl) -l (3H) -isobenzofyranone having physiological activity.
  • the present invention relates to the specific physiological activity of these compounds, allowing them to be used as “molecular tools)) or active drug substances that block interprotein interactions (roteip-prototype ip) or cause programmed cell death (apoptosis), as well as to a method the synthesis of such derivatives, to focused libraries containing these substances, to pharmaceutical compositions containing these compounds in the form of active substances, and also to a method for treating cancer.
  • Noskapin is an opium alkaloid, its content in the poppy Parave somniferum L. Paraveraceae reaches 11%, but noscapine is completely non-narcotic. Noskapin is approved for use as an antitussive, included in the United States Pharmacoreia (USP) (on the market since 1963), and is included as an active substance in the following drugs: Sarval, Loubekh, Narcotussip, Tussarip.
  • noscapine Ye K., Ke Y., Kesha N., Shanks J., Carr J., T. R., Retros J., Joshi H. Orium alkoid pozsarip is aptitumor agate that arrests metarhas ap ipodus arorthosis ip dividipell slls. Roc. Natl. Acad. Sretei. USA 1998, 95: 1601-1606]. Due to the unusual mechanism of interaction of noscapine with tubulin (a protein that forms the cytoskeleton) [Zhou J, et.al.
  • noscapine The low toxicity of noscapine is also very attractive, especially when compared with other antitumor substances [R. Lapg, et.al. The same alkoid posssarip is a louw tohisit agept with sigpifissapt aptumor effest ip melapoma. 62pd Appy Meat Sos Ipest Dertatol (Mau 9-12, Washington DC DC) 2001, Abst 568].
  • the unique properties of noscapine including its specific effect on microtubular dynamics, cell cycle arrest [Update JT, Type AE, Bozer S., Group J. KR, Crumrine C, J. J., T.
  • noscapine derivatives have been described, but with rare exceptions they are degradation products of one or two heterocyclic rings (for example, [Jasob A. l- (3-Phenylpropyl) -2-methyl-6,7-methylene-dioxy -8-methoxy-l, 2,3,4-tetrahoudroisoquipolip, and Rhartasolisillo active natrix derivatives. J Med Chet. 1965: 697-698]).
  • noscapine for example, (thio) carbamoyl analogues of N- demethylated noscapine [Aggarwal S., et al. A Compliance Supth Canalsis THERf Arul-Substitut N- ⁇ arbamoul / N-Thiosarbamoul N réelletocipe apd Relatome ⁇ omroshids. HeIv ⁇ h ⁇ issuedht, 85: 2002; et.al. US 6,376,516 Bl 04.23.2002; US 6,673,814 B2 06/01/2004]).
  • noscapine A derivatives containing a substituent in the 5-position of the isoquinoline ring are known (Table 1).
  • “Aheterocycle” means an aromatic or non-aromatic monocyclic or polycyclic system containing at least one nitrogen atom in a cycle.
  • An azaheterocycle may have one or more “cyclic substitutes”) systems.
  • "Aliphatic" radical means a radical obtained by removing a hydrogen atom from a non-aromatic C-H bond.
  • An aliphatic radical may additionally contain substituents — aliphatic or aromatic radicals defined in this section.
  • aliphatic radicals Representatives include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aralkenyl, aralkiloksialkil, aralkiloksikarbonilalkil, aralkyl, aralkynyl, aralkiloksialkenil, heteroaralkenyl, heteroaralkyl, geteroaralkiloksialkenil, geteroaralkiloksialkil, heteroaralkenyl, annelated arylcycloalkyl, annelated heteroarylcycloalkyl, annelated arylcycloalkenyl, annelated heteroarylcycloalkenyl, annelated arylheterocyclyl, annelated heteroarylheterocytes clyl, annelated arylheterocyclenyl
  • Alkenyl means an aliphatic linear or branched hydrocarbon group containing from 2 to 7 carbon atoms and including a carbon-carbon double bond. Branched means that one or more lower alkyl groups, such as methyl, ethyl or propyl, are attached to a linear alkenyl chain.
  • Preferred alkyl groups are methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbonylmethyl, benzyloxycarbonylmethylmethyl and pyridine.
  • Preferred alkenyl groups are ethenyl, propenyl, n-butenyl, isobutenyl, 3-methylbut-2-enyl, n-pentenyl, and cyclohexylbutenyl.
  • Alkenyloxy means an alkenyl-O— group in which alkenyl is defined in this section. Allyloxy and 3-butenyloxy are preferred alkenyloxy groups.
  • Alkenyloxyalkyl means an alkenyl-O-alkyl group in which alkyl and alkenyl are defined in this section.
  • Alkyl means an aliphatic hydrocarbon linear or branched group with 1-12 carbon atoms in the chain. Branched means that the alkyl chain has one or more "lower alkyl” substituents.
  • Alkyl may have one or more, same or different substituents (“alkyl substituents))), including halogen, alkenyloxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, aroyl, cyano, hydroxy, alkoxy, carboxy, alkynyloxy, aralkoxy, aryloxy, aryloxycarbonyl, alkyl , heteroarylthio, aralkylthio, arylsulfonyl, alkylsulfonylheteroaralkyloxy, annelated heteroarylcycloalkenyl, annelated heteroarylcycloalkyl, annelated heteroarylheterocyclenyl, annelated heteroarylhetero
  • Preferred alkyl groups are methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-pentyl, 3-pentil, methoxyethyl, carboxymethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, benzyloxycarbonylmethyl methoxycarbonylmethyl and piridilmetiloksikarbonilmetil .
  • Alkyloxyalkyl means an alkyl-O-alkyl group in which the alkyl groups are independent of each other and are defined in this section. Preferred alkyloxyalkyl groups are methoxyethyl, ethoxymethyl, n-butoxymethyl, methoxypropyl and isopropyloxyethyl.
  • Preferred alkyl hydroxycarbonyl groups are methoxycarbonyl, ethoxycarbonyl, n-butoxycarbonyl tert-butyloxycarbonyl., Iso-propyloxycarbonyl, benzylcarbonyl and phenethylcarbonyl.
  • Alkylthio means an alkyl-S group in which an alkyl group is defined in this section.
  • Alkoxy means an alkyl-O— group in which alkyl is defined in this section. Preferred alkyloxy groups are methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
  • Preferred alkoxycarbonylalkyl groups are methoxycarbonylmethyl and ethoxycarbonylmethyl and methoxycarbonylethyl and ethoxycarbonylethyl.
  • Amino group means R ⁇ R k + ⁇ N is a group substituted or unsubstituted by “a substituent of the amino group”, Rk a and Rk + D are defined in this section, for example, amino (H 2 N-), methylamino, diethylamino, pyrrolidine, morpholine, benzylamino or phenethylamino.
  • Amino acid means a natural amino acid or a non-natural amino acid, the meaning of which is defined in this section. Preferred amino acids are amino acids containing an ⁇ or ⁇ amino group.
  • Examples of natural amino acids are ⁇ -amino acids, they can be alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, series, threonine and cysteine.
  • Annelated cycle (condensed cycle) means a bi- or polycyclic system in which the annelated cycle and the cycle or polycyclic with which it is “annealed” have at least two common atoms.
  • Annelated apylheterocycloalkenyl means annelated aryl and heterocycloalkenyl, the meaning of which is defined in this section. Annelated arylheterocycloalkenyl can bind through any possible atom of the ring system.
  • the prefix "aza”, “okca” or “tia” before “heterocycloalkenyl” means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Annelated arylheterocycloalkenyl may have one or more “substituent ring systems)), which may be the same or different.
  • the nitrogen and sulfur atoms in the heterocyclenyl moiety can be oxidized to N-oxide, S-oxide or S-dioxide.
  • Representatives of annelated arylheterocycloalkenyls are indolinyl, ⁇ -2-oxoquinolinyl, 2H-1-oxoisoquinolinyl, 1,2-dihydroxinolinyl, and the like.
  • Annelated apylheterocycloalkyl means annelated aryl and heterocycloalkyl, the meaning of which is defined in this section. Annelated arylheterocycloalkyl can bind through any possible atom of the cyclic system.
  • the prefix "aza”, “okca” or “tia” before “heterocycloalkyl” means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Annelated arylheterocycloalkyl may have one or more “substituent ring systems)), which may be the same or different.
  • the nitrogen and sulfur atoms in the heterocyclyl moiety can be oxidized to N-oxide, S-oxide or S-dioxide.
  • Representatives of annelated arylheterocycloalkyls are indolyl, 1,2,3,4-tetrahydroisoxinoline, 1,3-benzodiocol, and the like.
  • “Annelated apylcycloalkenyl” means annelated aryl and cycloalkenyl, the meanings of which are defined in this section. Annelated arylcycloalkenyl can bind through any possible cyclic atom system.
  • Annelated arylcycloalkenyl may have one or more “cyclic system substitutes,” which may be the same or different.
  • Representatives of annelated arylcycloalkenyls are 1,2-dihydro-naphthalene, indene, etc.
  • Annelated apylcycloalkyl means annelated aryl and cycloalkyl, the meanings of which are defined in this section. Annelated arylcycloalkyl can bind through any possible atom of the cyclic system. Annelated arylcycloalkyl may have one or more “cyclic system substitutes,” which may be the same or different. Representatives of annelated arylcycloalkyls are indanine, 1,2,3., 4-tetrahydronaphthalene, 5,6,7,8-tetrahydronaphth-l-yl, etc.
  • Annelated heteroapylcycloalkenyl means annelated heteroaryl and cycloalkenyl, the meanings of which are defined in this section. Annelated heteroarylcycloalkenyl can bind through any possible atom of the cyclic system.
  • the prefix “aza”, “okca” or “tia” before “heteroapyl” means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Annelated heteroarylcycloalkenyl may have one or more “ring system substituents)), which may be the same or different.
  • the nitrogen atom in the heteroaryl moiety can be oxidized to N-oxide.
  • annelated heteroarylcycloalkenyls are 5,6-dihydroquinolinyl, 5,6-dihydroisoxinolinyl, 4,5-dihydro-lH-benimidazolyl, and the like.
  • “Annelated heteroapylcycloalkyl” means annelated heteroaryl and cycloalkyl, the meanings of which are defined in this section. Annelated heteroarylcycloalkyl can bind through any possible atom of the cyclic system.
  • the prefix "aza", “okca” or “tia" before “heteroapyl” means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Annelated heteroarylcycloalkyl may have one or more “ring system substituents)), which may be the same or different.
  • the nitrogen atom in the heteroaryl moiety can be oxidized to N-oxide.
  • Representatives of annelated heteroarylcycloalkyls are 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoxinolinyl, 4,5,6,7-tetrahydro-IH-benzimidazolyl, and the like.
  • Annelated heteroapylheterocycle means annelated heteroaryl and heterocyclenyl, the meanings of which are defined in this section. Annelated heteroaryl heterocyclenyl may bind through any possible atom of the cyclic system.
  • the prefix “aza”, “okca” or “tia” before “heteroapyl” means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Annelated heteroarylheterocyclenyl may have one or more “cyclic system substitutes” that may be the same or different.
  • the nitrogen atom in the heteroaryl moiety can be oxidized to N-oxide.
  • the nitrogen and sulfur atoms in the heterocyclenyl moiety can be oxidized to N-oxide, S-oxide or S-dioxide.
  • Representatives of annelated heteroarylheterocyclenyls are l, 2-dihydro [2,7] naphthyridinyl, 7,8-dihydro [l, 7] naphthyridinyl, 6,7-dihydro-3H-imidazo [4,5-c] pyridyl, etc.
  • “Annelated heteroapylheterocyclyl” means annelated heteroaryl and heterocyclyl, the meanings of which are defined in this section.
  • Annelated heteroaryl heterocyclyl can bind through any possible atom of the ring system.
  • the prefix “aza”, “okca” or “tia” before “heteroapyl” means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Annelated heteroarylheterocyclyl may have one or more “cyclic system substitutes,” which may be the same or different.
  • the nitrogen atom in the heteroaryl moiety can be oxidized to N-oxide.
  • the nitrogen and sulfur atoms in the heterocyclyl moiety can be oxidized to N-oxide, S-oxide or S-dioxide.
  • annelated heteroaryl heterocyclyls are 2,3-dihydro-III-pyrpolo [3,4-b] quinolin-2-yl, 2,3-dihydro-III-pyrpolo [3,4-b] indol-2-yl, l, 2,3,4-tetrahydro [l, 5] naphthyridinyl and the like.
  • “Aralkenyl” means an aryl-alkenyl group in which the meanings of aryl and alkenyl are defined in this section. For example, 2-phenethyl is an aralkenyl group.
  • Alkyl means an alkyl group substituted with one or more aryl groups, in which the meanings of aryl and alkyl are defined in this section. Examples of aralkyl groups are benzyl, 2,2-diphenylethyl or phenethyl. “Aralkylamino” means an aryl-alkyl-NH— group in which the meanings of aryl and alkyl are defined in this section.
  • Alkylcylfinyl means an aralkyl-SO— group in which the meaning of aralkyl is defined in this section.
  • “Aralkylcylphonyl” means aralkyl-SO 2 —the group in which the meaning of aralkyl is defined in this section.
  • “Aralkylthio” means an aralkyl-S- group in which the meaning of aralkyl is defined in this section.
  • Alkoxy means an aralkyl-O— group in which the meaning of aralkyl is defined in this section. For example, benzyloxy or 1- or 2-naphthylenmethoxy are aralkyl groups.
  • Alkoxyalkyl means an aralkyl-O-alkyl group in which the meanings of aralkyl and alkyl are defined in this section.
  • An example of an aralkyl-O-alkyl group is benzyloxyethyl.
  • An example of an aralkoxycarbonyl group is benzyloxycarbonyl.
  • An example of an aralkoxycarbonylalkyl group is benzyloxycarbonylmethyl or benzyloxycarbonylethyl.
  • Aryl means an aromatic monocyclic or polycyclic system comprising from 6 to 14 carbon atoms, preferably from 6 to 10 carbon atoms.
  • Aryl may contain one or more “substituents of the cyclic system)), which may be the same or different.
  • Representative aryl groups are phenyl or naphthyl, substituted phenyl or substituted naphthyl.
  • Aryl can be annelated with a non-aromatic ring system or heterocycle.
  • Aminyl means an aryl-SO— group in which the meaning of aryl is defined in this section.
  • Amylcylphone means apyl-SO 2 —the group in which the meaning of aryl is defined in this section.
  • Apilthio means an aryl-S- group in which the meaning of aryl is defined in this section. Representative arylthio groups are phenylthio and 2-naphthylthio. “Apoylamino” means an aroyl-NH group in which the meaning of aroyl is defined in this section.
  • “Aromatic” radical means a radical obtained by removing a hydrogen atom from an aromatic C — H bond.
  • the “aromatic” radical includes the aryl and heteroaryl rings defined in this section. Aryl and heteroaryl rings may additionally contain substituents — aliphatic or aromatic radicals defined in this section.
  • Aromatic radicals include aryl, annelated cycloalkenylaryl, annelated cycloalkylaryl, annelated heterocyclylaryl, annelated heterocyclylaryl, heteroaryl, annelated cycloalkylheteroaryl, annelated cycloalkenylheteroaryl heteroeryl heteroaryl.
  • “Aromatic cycle” means a planar cyclic system in which all atoms of the cycle participate in the formation of a single conjugation system including, according to the Hückel rule, (4n + 2) ⁇ -electrons (n is a non-negative integer). Examples of aromatic cycles are benzene, naphthalene, anthracene, and the like.
  • hetero matric cycles In the case of “hetero matric cycles”, ⁇ electrons and p electrons of heteroatoms participate in the conjugation system; their total number is also equal to (4n + 2). Examples of such cycles are pyridine, thiophene, pyrrole, furan, thiazole and the like.
  • the aromatic cycle may have one or more “substitutes for the cyclic)) system and can be annelated with a non-aromatic cycle, heteroaromatic or heterocyclic system.
  • acylamino means an acyl-NH— group in which the meaning of acyl is defined in this section.
  • Bifunctional reagent means a chemical compound having two reaction centers participating simultaneously or sequentially in the reactions.
  • bifunctional reagents are reagents containing a carboxyl group and an aldehyde or ketone group, for example, 2- formylbenzoic acid, 2- (2-oxo-ethylcarbamoyl) -benzoic acid, 2- (3-formylthiophen-2-yl) -benzoic acid or 2- (2-formylphenyl) -thiophene-3-boan.
  • 1,2-vinyl vinyl radical means a —CH ⁇ CH— group which contains one or more identical or different alkyl substituents, the meaning of which is defined in this section.
  • Halogen means fluorine, chlorine, bromine and iodine. Fluorine, chlorine and bromine are preferred.
  • Hetero-linked loop means that a loop that attaches (annelates or condenses) to another loop or polycycle contains at least one heteroatom.
  • Heteroapalkenyl means a heteroaryl alkenyl group in which heteroaryl and alkenyl are defined in this section.
  • heteroarylalkenyl includes a lower alkenyl group.
  • Representatives of heteroarylalkenyls are A-pyridylvinyl, thienylethenyl, imidazolylethenyl, pyrazinylethenyl and the like.
  • Heteroapalkyl means a heteroaryl-alkyl group in which heteroaryl and alkyl are defined in this section.
  • heteroarylalkyls are pyridylmethyl, thienylmethyl, furylmethyl, imidazolylmethyl, pyrazinylmethyl, and the like.
  • “Heteroapalkyloxy” means a heteroarylalkyl-O— group in which heteroarylalkyl is defined in this section.
  • Preferred heteroarylalkyloxy groups are 4-pyridylmethyloxy, 2-thienylmethyloxy and the like.
  • Representative heteroaroyls are nicotinoyl, thienoyl, pyrazoloyl, etc.
  • Heteroapyl means an aromatic monocyclic or polycyclic system comprising from 5 to 14 carbon atoms, preferably from 5 to 10, in which one or more carbon atoms are substituted with heteroatoms or heteroatoms such as nitrogen, sulfur or oxygen.
  • the prefix “aza”, “okca” or “tia” before “heteroapyl” means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • the nitrogen atom in the heteroaryl may be oxidized to N-oxide.
  • a vegetarian can have one or more “cyclic system substitutes,” which can be the same or different.
  • heteroaryls are pyrrolyl, furanyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, isoxazolyl, isothiazolyl, tetrazolyl, ochazolyl, thiazolyl, pyrazolyl, furazanyl, triazolyl, 1,2,4-thiadiazolyl, pyridoxyninyl phthalazinyl, imidazo [l, 2-a] pyridinyl, imidazo [2, lb] thiazolyl, benzofurazanil, indolyl, azaindolyl, benzimidazolyl, benzothiazenyl, quinolinyl, imidazolyl, thienopyridinopyridinyl, 2,4-thiazinyl, thienopyrrolyl, furopyrrolyl, etc. “Heteroapylcylphonyl
  • Heterocycle means a non-aromatic monocyclic or polycyclic system comprising from 3 to 13 carbon atoms, preferably from 5 to 13 carbon atoms, in which one or more carbon atoms are replaced by a hetero atom such as nitrogen, oxygen, sulfur and which contains at least , one carbon-carbon double bond or carbon-nitrogen double bond.
  • aza, "okca” or “thia” before heterocyclenyl means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Heterocyclenyl may have one or more “cyclic system substitutes,” which may be the same or different.
  • heterocyclenyl can be oxidized to N-oxide, S-oxide or S-dioxide.
  • Representative heterocyclenyls are 1,2,3,4-tetrahydropyridine, 1,2-dihydropyridine, 1,4-dihydropyridine, 2-pyrpolinyl, 3-pyrpolinyl, 2-imidazolyl, 2-pyrazolinyl, dihydrofuranyl, dihydrothiophenyl and the like.
  • Heterocyclyl means a non-aromatic saturated monocyclic or polycyclic system comprising from 3 to 10 carbon atoms, preferably from 5 to 6 carbon atoms, in which one or more carbon atoms are replaced by a heteroatom such as nitrogen, oxygen, sulfur.
  • a heteroatom such as nitrogen, oxygen, sulfur.
  • the prefix "aza”, “okca” or “thia” before heterocyclyl means the presence in the cyclic system of a nitrogen atom, an oxygen atom or a sulfur atom, respectively.
  • Heterocyclyl may have one or more “cyclic system substitutes,” which may be the same or different.
  • the nitrogen and sulfur atoms in the heterocyclyl can be oxidized to N-oxide, S-oxide or S-dioxide.
  • heterocyclyl are piperidine, pyrrolidine, piperazine, morpholine, thiomorpholine, thiazolidine, 1,4-dioxane, tetrahydrofuran, tetrahydrothiophene, etc.
  • Heterocyclyloxy means a heterocyclyl-O— group in which heterocyclyl is defined in this section.
  • “Hydrate” means a solvate in which water is a molecule or molecules of a solvent.
  • Hydroalkyl means a HO-alkyl group in which alkyl is defined in this section.
  • Substituent means a chemical radical that attaches to the scaffold
  • Alkyl substituent means a substituent attached to alkyl, alkenyl, the meaning of which is defined in this section.
  • Alkyl substituent is hydrogen, alkyl, halogen, alkenyloxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, aroyl, cyano, hydroxy, alkoxy, carboxy, alkynyloxy, aralkoxy, aryloxy, aryloxycarbonyl, alkylthio, heteroarylthio, aralkylthio, arylsulfonyl, alkilsulfonilgeteroaralkiloksi, annelated heteroarylcycloalkenyl , annelated heteroarylcycloalkyl, annelated heteroarylheterocyclenyl, annelated heteroarylheterocyclyl, annelated arylcycloalkenyl, annelated arylcycloalkyl, annel
  • Preferred alkyl groups are methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-pentyl, 3-pentil, methoxyethyl, carboxymethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, benzyloxycarbonylmethyl and methoxycarbonylmethyl piridilmetiloksikarbonilmetil .
  • the meaning of the alkyl substituents is defined in this section.
  • Amino group substituent "means a substituent attached to an amino group.
  • the amino substituent is hydrogen, alkyl, cycloalkyl, aryl, geheroaril, heterocyclyl, acyl, aroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, geterotsiklilaminokarbonil, alkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocyclylaminothiocarbonyl, annelated heteroarylcycloalkenyl, annelated heteroarylcycloalkyl, annelated heteroarylheterocyclenyl, annelated heteroarylheterocyclyl, annelated arylcycloalkenyl, annelated aryl
  • Carbamoyl substituent means a substituent attached to a carbamoyl group, the meaning of which is defined in this section.
  • the meaning of “carbamoyl substitutes” is defined in this section.
  • Nucleophilic substituent means a chemical radical that is attached to scaffold by reaction with a nucleophilic reagent, for example, selected from the group of primary or secondary amines, alcohols, phenols, mercaptans and thiophenols.
  • “Substituent cyclic system)) means a substituent attached to an aromatic or non-aromatic cyclic system, including hydrogen, alkylalkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, hydroxyalkyl, amino, aminoalkyl, alkoxy, aryloxy, acyl, aroyl, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkyloxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, arylalkyloxyalkyl, geterotsiklilalkiloksialkil, alkylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylsulfinyl, arylsulfinyl, geterotsiklilsulfinil, al
  • Electrophilic substituent means a chemical radical that attaches to scaffold as a result of reaction with an electrophilic reagent, for example, selected from the group of organic acids or their derivatives (anhydrides, imidazolides, halides), ethers of organic sulfonic acids or organic sulfonyl chlorides, organic halides, organic isocyanides organic isothiocyanates.
  • Amino amino group means an R k a R k + 1 a N group in which R k a and R k + i a are amino substituents as defined in this section.
  • Substituted carboxyl means a C (O) OR group.
  • the substituted carboxyl has a substituent R, including alkenyl, alkyl, aryl, heteroaryl, heterocyclyl, the meaning of which is defined in this section.
  • Substituted mercapto group means an SR, S (O) R or S (02) R group in which the substituent R is alkenyl, alkyl, aryl, heteroaryl, heterocyclyl, the meanings of which are defined in this section.
  • “Protection group” means a chemical radical that attaches to a scaffold or intermediate to synthesize the amino group in multifunctional compounds, including but not limited to: amide a substituent such as formyl, optionally substituted acetyl (for example trichloroacetyl, trifluoroacetyl, 3-phenylpropionyl, etc.), optionally substituted benzoyl, etc .; a carbamate substituent, such as optionally substituted C 1 -C 7 alkyloxycarbonyl, for example, methyloxycarbonyl, ethyloxycarbonyl, tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (Fmoc), etc .; optionally substituted C 1 -C 7 alkyl substituent, for example, tert-butyl, benzyl, 2,4-dimethixibenzyl, 9-phenylphyloinyl and others; sulf
  • Protective groups are described in the book: Protective groups and organic supervisor, Third Edite Grepe, TW ap Wuts, PGM 1999, p. 494-653. Publishing house Johan Willeu & Sops, Ips, New York, Shikhester, Wehim, Vrisbape, Toropto, S ⁇ pgarore.
  • Protected primary or secondary amine “means a group of the formula Rk a Rk + i a N-, in which R k a represents a protective group PG and R k + i a represents hydrogen," a substituent of the amino group ", the meaning of which is defined in this section e.g.
  • “Inert substituent (or” not interfering, “Nopperfer substitupt”) means a low or non-reactive radical, including but not limited to C 1 - C 7 alkyl, C 2 - C 7 alkenyl, C 2 - C 7 alkynyl, C 1 - C 7 alkoxy, C 7 - C 12 aralkyl substituted with inert substituents of aralkyl, C 7 - C 12 heterocyclylalkyl, substituted with inert substituents of heterocyclylalkyl, C 7 - C 12 alkaryl, C 3 - C 10 cycloalkyl, C 3 - C 10 cycloalkenyl, phenyl, substituted phenyl, toluyl, xylene, biphenyl, C 2 - C 12 alkoxyalkyl, C 2 - C 10 alkylsulfinyl, C 2 - C 10 alkylsulfonyl, (CH 2
  • Carbamoyl may have one or more identical or different "carbamoyl substituents" R k a and R réelle + ⁇ including hydrogen, alkenyl, alkyl, aryl, heteroaryl, heterocyclyl, the meaning of which is defined in this section.
  • Carbamoylheterocycle means an azaheterocycle containing as
  • Kembocycle means a mono- or polycyclic system consisting only of carbon atoms. Carbocycles can be either aromatic or alicyclic.
  • Alicyclic polycycles may have one or more common atoms.
  • spiro-carbocycles are formed (for example, spiro [2.2] pentane), in the case of two
  • “Combinative library” means a collection of compounds obtained by parallel synthesis designed to search for a hit or leader compound, as well as to optimize the physiological activity of a hit or leader, each library compound corresponding to a common scaffold, and the library is a collection of related homologues or analogues.
  • “Methylene radical” means —CH 2 — a group that contains one or two identical or different “alkyl substituents”, the meanings of which are defined in this section.
  • a non-aromatic cycle may have one or more “substituent cyclic)) systems and may be annelated with aromatic, heteroaromatic or heterocyclic systems. Examples of non-aromatic rings are cyclohexane or piperidine, examples of a partially saturated ring are cyclohexene or piperidine.
  • Non-natural amino acid means an amino acid of a non-nucleic nature.
  • unnatural amino acids are the D-isomers of natural ⁇ -amino acids, aminobutyric acid, 2-aminobutyric acid, ⁇ -aminobutyric acid, N- ⁇ -alkylated amino acids, 2,2-dialkyl- ⁇ -amino acids, 1-amino-cycloalkyl carboxylic acids, ⁇ -alanine, 2-alkyl- ⁇ -alanines, 2-cycloalkyl- ⁇ -alanines, 2-apyl- ⁇ -alanines, 2-heteroapyl- ⁇ -alanines, 2-heterocyclyl- ⁇ -alanines and (1-amino-cycloalkyl ) -cyclic acids in which the meanings of alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are defined in this section.
  • Optional aromatic cycle means a cycle that can be either an aromatic cycle or a non-aromatic cycle, the meanings of which are defined in this section.
  • Optionally substituted radical means a radical without substituents or containing one or more substituents.
  • Optionally annelated (condensed) cycle means a condensed, non-condensed cycle, the meanings of which are defined in this section.
  • “Lower alkyl” means a linear or branched alkyl with 1-4 carbon atoms.
  • Parallel synthesis means a method for conducting chemical synthesis of a combinatorial library of individual compounds.
  • 1,3-Propylene radical means —CH 2 —CH 2 —CH 2 — a group that contains one or more identical or different “alkyl substituents”, the meanings of which are defined in this section.
  • Leader means a compound with outstanding (maximum) physiological activity associated with a specific biological target related to a specific (or several) pathology or disease.
  • Compound-hit (“hit”) means a compound that exhibits the desired physiological activity during the initial screening process.
  • “Sweet group” means R k a R k + i a NSO 2 is a group substituted or unsubstituted by “a substituent of the amino group” R k a and R k + i a , the meanings of which are defined in this section.
  • Cylfonyl means R-SO 2 - a group in which R is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, annelated heteroarylcycloalkenyl, annelated heteroaryl heterocyclylalkenyl, annelated heteroaryl heterocyclylalkylalkyl the meaning of which is defined in this section.
  • Tempolate means the general structural formula of a group of compounds or compounds included in the “combinational library)).
  • Thiocarbamoyl may have one or more identical or different “amino group substitutes” R k a and R k + i a , the meaning of which is defined in this section, for example, including alkenyl, alkyl, aryl, heteroaryl, heterocyclyl, the meaning of which is defined in this section.
  • Cycloalkyl means a non-aromatic mono- or polycyclic system containing from 3 to 10 carbon atoms. Cycloalkyl may have one or more “substituents of the cyclic system)), which may be the same or different. Representative cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decalin, norbornyl, adamant-1-yl and the like. Cycloalkyl can be annelated with an aromatic ring or heterocycle. Preferred “substituents of the cyclic system)) are alkyl, aralkoxy, hydroxy or R k a R k + i a N, the meaning of which is defined in this section.
  • Representatives of cycloalkylcarbonyl groups are cyclopropylcarbonyl or cyclohexylcarbonyl.
  • “Cycloalkoxy” means a cycloalkyl-O— group in which the meaning of cycloalkyl is defined in this section.
  • “Pharmaceutical Composition” means a composition comprising a compound of formula I and at least one of the components selected from the group consisting of pharmaceutically acceptable and pharmacologically compatible excipients, solvents, diluents, carriers, excipients, distributing and perceptive means, means deliveries such as preservatives, stabilizers, fillers, grinders, moisturizers, emulsifiers, suspending agents, thickeners, sweeteners, perfumes, flavors, antibacterial agents you, fungicides, lubricants, prolonged delivery regulators, the choice and ratio of which depends on the nature and method of administration and dosage.
  • suspending agents examples include ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, as well as mixtures of these substances. Protection against the action of microorganisms can be provided with a variety of antibacterial and antifungal agents, for example, parabens, chlorobutanol, sorbic acid and the like.
  • the composition may also include isotonic agents, for example, sugars, sodium chloride and the like.
  • the prolonged action of the composition can be achieved using agents that slow down the absorption of the active principle, for example, aluminum monostearate and gelatin.
  • suitable carriers, solvents, diluents and delivery vehicles are water, ethanol, polyalcohols, and also mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate).
  • excipients are lactose, milk sugar, sodium citrate, calcium carbonate, calcium phosphate and the like.
  • grinders and distributors are starch, alginic acid and its salts, silicates.
  • lubricants are magnesium stearate, sodium lauryl sulfate, talc, and high molecular weight polyethylene glycol.
  • the pharmaceutical composition for oral, sublingual, transdermal, intramuscular, intravenous, subcutaneous, local or rectal administration of the active principle, alone or in combination with another active principle, can be administered to animals and humans in a standard administration form, in the form of a mixture with traditional pharmaceutical carriers.
  • Suitable unit dosage forms include oral forms such as tablets, gelatine capsules, pills, powders, granules, chewing gums and oral solutions or suspensions, sublingual and buccal administration forms, aerosols, implants, local, transdermal, subcutaneous, intramuscular, intravenous, intranasal or intraocular forms of administration and rectal forms of administration.
  • “Pharmaceutically acceptable salt” means the relatively non-toxic organic and inorganic salts of the acids and bases of the present invention.
  • salts can be prepared in situ during the synthesis, isolation or purification of compounds or prepared specially.
  • base salts can be prepared specifically based on the purified free base of the claimed compound and a suitable organic or inorganic acid.
  • salts thus obtained are hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valeriates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, tosylates, citrates, maleates, fumarates, succinates, tartrates mesylates, malonates, salicylates, propionates, ethanesulfonates, benzenesulfonates, sulfamates and the like.
  • Salts of the claimed acids can also be specially prepared by reacting the purified acid with a suitable base, and metal and amine salts can be synthesized.
  • Metal salts include sodium, potassium, calcium, barium, zinc, magnesium, lithium and aluminum salts, the most desirable of which are sodium and potassium salts.
  • Suitable inorganic bases from which metal salts can be obtained are hydroxide, carbonate, sodium bicarbonate and hydride, potassium hydroxide and bicarbonate, potash, lithium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide.
  • amines and amino acids are selected that are sufficiently basic to form a stable salt and are suitable for medical use (in particular, they should have low toxicity).
  • amines include ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, benzylamine, dibenzylamine, dicyclohexylamine, piperazine, ethylpiperidine, tris (hydroxymethyl) aminomethane and the like.
  • tetraalkylammonium hydroxides for example, such as choline, tetramethylammonium, tetraethylammonium and the like, can be used for salt formation.
  • amino acids the main amino acids can be used - lysine, ornithine and arginine.
  • “Focussed library” means a combinatorial library or a collection of several combinatorial libraries, or a collection of libraries and substances specially organized in order to increase the likelihood of finding hits and leaders or to increase the efficiency of their optimization.
  • the design of focused libraries is associated with a directed search for effectors (inhibitors, activators, agonists, antagonists, etc.) of specific biological targets (enzymes, receptors, ion channels, etc.).
  • “Fragment” means the structural formula of a part of a molecule characteristic of a group of compounds, or the molecular framework characteristic of a group of compounds or compounds included in a “combinational library)).
  • 1,2-Ethyl radical means —CH 2 —CH 2 — a group that contains one or more of the same or different “alkyl substituents”, the meanings of which are defined in this section.
  • the aim of the present invention are new azaheterocycles, a method for their preparation and use.
  • R is an amino substituent selected from alkyl
  • R is an amino substituent selected from alkyl
  • R represents a cyclic system substituent selected from optionally substituted alkyl, optionally substituted aryl, optionally substituted and optionally fused heteroaryl
  • Ar represents aryl or heteroaryl.
  • more preferred compounds are also derivatives of (R, S) -nocapine of the general formula 1.2:
  • R 3 and R 4 independently from one another are the same or different substituents of the amino group selected from hydrogen, alkyl, aryl, or R 3 and R 4 together with the nitrogen atom to which they are bonded, are shorted through R 3 and R 4 azaheterocycle.
  • more preferred compounds are also derivatives of (R, S) -nocapine of the general formula 1.3:
  • R 3 and R 4 have the meanings indicated for compounds of General formula 1.2.
  • the most preferred compounds of general formula 1 are: 3- (9-iodo-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] dioxolo- [4,5-g] isoxinolin-5- il) -6,7-dimethoxy-3H-isobenzofuran-1-one 1 (1), 3 ⁇ (4-methoxy-6-methyl-9-chloromethyl-5,6,7,8-tetrahydro [l, 3] -dio-colo [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-l-one 1 (2), 5- (4,5-dimethoxy-3-oxo-l, 3 -dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-
  • the most preferred compounds of general formula 1.1 are: 3- (9-phenyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] dioxolo- [4,5-g] isoxinoline-5- il) -b, 7-dimethoxy-3H-isobenzofyran-1-one 1.1 (1), 3- (9-p-tolyl-4-methoxy-6-methyl-5,6,7,8- tetrahydro [l, 3] dioxol- [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-l-one 1.1 (2), 3- [9- (4-methoxyphenyl) -4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l, 3] dioxol- [4,5-g] isoxinolin-5-yl] -6,7-dimethoxy-3H-isobenzofyran- l-OH
  • the most preferred compounds of general formula 1.2 are: 3- (9-benzylaminomethyl-4-methoxy-6-methyl-5,6,7,8-tetra-hydro [l, 3] dioxol [4,5-g] isoxinolin-5 -yl) -6,7-dimethoxy-3H-isobenzofyran-l-one 1.2 (1), 3- (9-diethylaminomethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l, 3] dioxol [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzo-fyran-l-one 1.2 (2), 3- (9-N-pyrpolidinomethyl-4-methoxy- 6-methyl-5,6,7,8-tetrahydro- [l, 3] dioxole [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzo-fyran-l-one
  • the most preferred compounds of general formula 1.3 are: 5- (4,5-dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-5,6,7,8- tetrahydro- [l, 3] dioxol [4,5-g] isoxinolin-9-sulfonylamide 1.3 (1), 6,7-dimethoxy-3- [4-methoxy-6-methyl-9- (pyrpolidin-l-cylfo -nyl) -5,6,7,8-tetrahydro- [l, 3] dioxole [4,5-g] isoxinolin-5-yl] -ZH-isobenzofyran-l-one 1.3 (2), 6.7- dimethoxy-3- [4-methoxy-6-methyl-9- (piperidin-l-sulfonyl) -5,6,7,8-tetrahydro- [l, 3] dioxol [4,5
  • the aim of this invention is a method for producing compounds of General formula 1 or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and / or hydrates. According to the present invention, methods have been developed for the preparation of derivatives of (R, S) -nocapine, which allow preserving the optical activity inherent in the starting alkaloid.
  • a method for producing 3- (9-iodine-4-methoxy-b-methyl-5,6 5 7,8-tetrahydro [l, 3] dio-colo- [4,5-g] isoxinolin-5-yl) is developed -6,7-dimethoxy-3H-isobenzofyran-1-one 1 (1), consisting in the action of ICl on (R, S) -scapine NSC in acetic acid according to the following scheme:
  • a method for producing 3- (9-chloromethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] -dioxol [4,5-g] isoxinolin-5-yl) is developed -6,7-dimethoxy-3H-isobenzofyran-1-one 1 (2), which consists in the action of thionyl chloride on 3- (9-hydroxymethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [ l, 3] -dio-colo [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-l-one A-04 according to the following scheme:
  • a method for producing 5- (4,5-dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l , 3] dioxol [4,5-g] isoxynolin-9-carbaldehyde 1 (3), which consists in the action of hexamethylenetetramine 2 on 3- (9-chloromethyl-4-methoxy-6-methyl-5,6,7,8- tetrahydro [l, 3] - dioxol [4,5-g] isoxinolin-5-yl) -b, 7-dimethoxy-3H-isobenzofyran-l-one 1 (2) in an organic solvent medium according to the following scheme:
  • a method for producing 5- (4,5-dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l , 3] dioxol [4,5-g] isoxinolin-9-carbonitrile 1 (4), which consists in the action of copper (I) cyanide on 3- (9-bromo-6-methyl-5,6,7,8-tetrahydro [l, 3] dioxol- [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-l-one A-Ol or 9-iodine-4-methoxy-6-methyl- 5,6,7,8-tetrahydro [l, 3] dioxol- [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-1-one 1
  • a method for producing 5- (4,5-dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-5, b, 7,8-tetrahydro- [l , 3] dioxol [4,5-g] isoxynolin-9-carboxylic acid 1 (5) by hydrolysis of 5- (4,5-dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy 6-methyl-5,6,7,8-tetrahydro- [l, 3] dioxole [4,5-g] isoxinolin-9-carbonitride 1 (4) according to the following scheme:
  • a method for producing 3- (9-methoxymethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] -dio-colo [4,5-g] isoxynolin-5-yl) is developed -6,7-dimethoxy-3H-isobenzofyran-1-one 1 (6) by the interaction of 3- (9-chloromethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] -di -oxo [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-1-one 1 (2) with methanol in the presence of a base according to the following scheme:
  • a method for producing 5- (4,5-dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l , 3] [4,5-g] isoxynolin-9-sulfonyl chloride 1 (7), consisting in the action of chlorosulfonic acid on (R, S) -scapine NSC according to the following scheme:
  • a method for producing derivatives of (R 3 S) - noscapine of general formula 1.1 which consists in the interaction of 3- (9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] dioxol- [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-1-one A-Ol or its iodide analog 1 (1) in the presence of a palladium catalyst with an aryl- or heteroaryl boron derivatives of the general formula 3 according to the following scheme:
  • Cross-coupling is carried out in a polar aprotic solvent (dimethylformamide, N-methylpyrrolidone, dimethoxyethane or the like), in the presence of 1-5 equivalents of an inorganic base (carbonates, fluorides, bicarbonates or fully substituted alkali and alkaline earth metal phosphates, for example, cesium carbonate, potassium fluoride as well as silver phosphate) and 5-25 mol% of the catalyst, which is used as palladium chloride or acetate, as well as their complexes with organophosphorus ligands, such as triphenylphosphine.
  • the reaction is carried out by heating at a temperature of 100-170 0 C, in the conditions of microwave irradiation or without it.
  • a stereospecific method for the synthesis of noscapine derivatives of the general formula 1.1 characterized in that the cross-combination of A-01 and (get) acylboric acids is carried out in polar aprotic solvents (for example, dimethoxyethane) in the presence of 3-4 equivalents of cesium carbonate and 10-20 mol. % complex of palladium chloride with triphenylphosphine at 130-150 0 C under the influence of microwave irradiation.
  • polar aprotic solvents for example, dimethoxyethane
  • the developed method for the preparation of (R, S) -nocapine derivatives of the general formula 1.2 consists in reductive amination of 5- (4,5-dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6 -methyl-5,6,7,8-tetrahydro- [l, 3] dioxol [4,5-g] isoxinolin-9-carbaldehyde 1 (3) amines of general formula 4 in an organic solvent medium according to the following scheme:
  • the developed method for producing derivatives of (R, S) -nocapine of the general formula 1.3 consists in the interaction of 5- (4,5-dimethoxy-3-oxo-1, 3-dihydroisobenzofyran-1-yl) -4-methoxy-6- methyl-5,6,7,8-tetrahydro- [l, 3] dioxol [4,5-g] isoxinolin-9-sulfonyl chloride 1 (7) with amines of the general formula 4 according to the following scheme:
  • the compounds of general formula 1 of the present invention can form hydrates or pharmaceutically acceptable salts.
  • Inorganic acids and organic acids for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, propionic acid, trifluoroacetic acid, maleic acid, tartaric acid, methanesulfonic acid, benzene sulfonic acid, can be used. , paratoluenesulfonic acid.
  • the compounds of general formula 1 or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and / or hydrates can be used as an active ingredient for the treatment and prevention of influenza and acute viral respiratory diseases, in addition, this invention also provides a method for the treatment and prevention of these diseases, including the introduction of sick or susceptible to these diseases patients chemical compounds of the present invention in effective therapist ble doses.
  • the aim of the present invention is a new combinatorial library for determining leader compounds.
  • the aim of the present invention is a new focused library for determining leader compounds.
  • the aim of the present invention is a new pharmaceutical composition having anticarcinogenic activity.
  • compositions containing, as an active ingredient, the compounds of general formula 1 or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and / or hydrates, as well as pharmaceutically acceptable excipients.
  • pharmaceutically acceptable excipients are meant diluents, excipients and / or carriers used in the pharmaceutical field.
  • the compounds of general formula 1 of the present invention can be used in combination with other active ingredients, provided that they do not cause undesirable effects, for example, allergic reactions.
  • compositions of the present invention can be mixed for the manufacture of various forms, and they may include traditional pharmaceutical carriers, for example, oral forms (such as tablets, gelatine capsules, pills, solutions or suspensions) ; injection forms (such as injectable solutions or suspensions, or dry powder for injection, which only requires the addition of water for injection before use); local forms (such as ointments or solutions).
  • traditional pharmaceutical carriers for example, oral forms (such as tablets, gelatine capsules, pills, solutions or suspensions) ; injection forms (such as injectable solutions or suspensions, or dry powder for injection, which only requires the addition of water for injection before use); local forms (such as ointments or solutions).
  • the carriers used in the pharmaceutical compositions of the present invention are carriers that are used in the pharmaceutical field to obtain common forms, including: binders, lubricants, disintegrants, solvents, diluents, stabilizers, suspending agents, are used in oral forms colorless agents, flavoring agents; antiseptic agents, solubilizers, stabilizers are used in injection forms. In local forms, bases, diluents, lubricants, antiseptic agents are used. Pharmaceutical preparations may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically). If any medicinal substance is not stable under the conditions of the stomach, it can be used to make tablets coated with a film of a substance soluble in the stomach or intestines.
  • the clinical dosage of the compounds of general formula 1 or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and / or hydrates in patients may be adjusted depending on the therapeutic the effectiveness and bioavailability of the active ingredients in the body, the speed of their metabolism and excretion from the body, as well as depending on the age, gender and stage of the patient’s disease.
  • the daily dose in adults is usually 10 ⁇ 500 mg, preferably 50 ⁇ 300 mg. Therefore, during the preparation of the pharmaceutical compositions of the present invention as dosage units, the above effective dosage must be taken into account, with each dosage unit of the preparation containing 10 ⁇ 500 mg of the compound of general formula 1, preferably 50 ⁇ 300 mg. In accordance with the instructions of a doctor or pharmacist, these drugs can be taken several times during certain periods of time (preferably from one to six times).
  • the aim of the present invention is a method of treating and preventing the development of various diseases of warm-blooded animals and people associated with tumor growth, in particular various types of human cancers.
  • This goal is achieved by administering to a warm-blooded animal or human a pharmaceutical composition containing, as an active ingredient, compounds of the general formula 1 or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and / or hydrates, as well as pharmaceutically acceptable excipients.
  • the aim of the present invention are antimitotic compounds and substances for experimental (ip vivo, ip vitro) studies of processes that stop cell division, used as “pharmaceutical tools)).
  • Example 1 3- (9-Bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] dioxol- [4,5-g] isoxinolin-5-yl) -6, 7-dimethoxy-3H-isobenzofyran-l-one A-Ol.
  • NSC N-(2-amino-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] dioxol- [4,5-g] isoxinolin-5-yl) -6, 7-dimethoxy-3H-isobenzofyran-l-one A-Ol.
  • reaction mixture was poured onto 60 ml of a saturated ammonia solution cooled to 0 ° C.
  • the colorless precipitate formed is filtered off, washed thoroughly with water, dried, and 63% A-Ol is obtained.
  • Example 2 3- (9-Iodo-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] Dioxol- [4,5-g] isoxinolin-5-yl) -6, 7-dimethoxy-3H-isobenzofyran-l-one 1 (1).
  • a solution of 206 mg (0.5 mmol) of NSC in 4 ml of AcOH was mixed with 100 mg (0.6 mmol) of ICl and stirred for 3 hours at 50 ° C (reaction control using LC-MS). The reaction mass is neutralized with ammonia while cooling with ice. The precipitate is filtered off, washed with water and dried. 246 mg (71%) 1 (1) is obtained.
  • Example 3 3- (9-Chloromethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] -Di-oxo [4,5-g] isoxinolin-5-yl) - 6,7-dimethoxy-3H-isobenzofyran-l-one hydrochloride 1 (2).
  • a solution of 0.45 g (0.27 ml, 3.75 mmol) of SOCl 2 in 3 ml of dichloromethane was added dropwise to a solution of 1.11 g (2.5 mmol) of 5-HOCH 2 -NSC A-04 in 10 ml of dichloromethane, maintaining the temperature of the reaction mixture in the range of 0-3 C.
  • Example 4 5- (4,5-Dimethoxy-3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l, 3] dioxol [4,5-g] isoxinolin-9-carbaldehyde 1 (3).
  • a solution of 200 mg (0.4 mmol) of hydrochloride 1 (2) in 2 ml of water is mixed with 0.6 ml of IN NaOH.
  • the resulting emulsion was extracted with chloroform, the extract was dried with anhydrous Na 2 SO 4 , concentrated to 2 ml and boiled with 70 mg (0.5 mmol) of hexamethylenetetramine.
  • Example 5 The General method of obtaining 5- (4,5-dimethoxy ⁇ 3-oxo-l, 3-dihydroisobenzofyran-l-yl) -4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l , 3] dioxol [4,5-g] isoxinolin-9-carbonitrile 1 (4).
  • reaction mass is cooled to 4 ° C and 15 ml of ammonia and 15 ml are added with stirring. chloroform.
  • the organic layer was separated, washed with water, dried over Na 2 SO 4 , filtered, the resulting solution was stirred for 15 minutes with activated carbon, filtered and concentrated. The precipitate was filtered off and recrystallized from isopropanol.
  • Example 6 3- (9-Methoxymethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] -Di-oxo [4,5-g] isoxinolin-5-yl) - 6,7-dimethoxy-3H-isobenzofyran-l-one 1 (5).
  • 0.5 ml of diisopropylethylamine is added to a suspension of 100 mg (0.2 mmol) 1 (2) in 3 ml of MeOH, the mixture is boiled until the initial hydrochloride is completely dissolved, cooled, treated with water, the precipitated oil is extracted with EtOAc, the organic layer is dried over Na 2 SO 4 , and the solvent is evaporated.
  • Example 7 General method for producing 3- (9-apyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro [l, 3] dioxol- [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzofyran-1-ones of the general formula 1.1.
  • Activated carbon is added to the combined aqueous solution, brought to a boil, filtered hot through celite, the filtrate is cooled and treated with an excess of aqueous solution NH 3 .
  • the precipitate after keeping the mixture in the refrigerator for 2-3 hours, is filtered off, washed with plenty of water, and 160 mg of a colorless product 1.1 are obtained.
  • Example 7 General method for producing 3- (9-aminomethyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro- [l, 3] dioxolo [4,5-g] isoxinolin-5-yl) -6,7-dimethoxy-3H-isobenzo-fyran-1-ones 1.2.
  • Example 8 General method for producing 6,7-Dimethoxy-3- [4-methoxy-6-methyl-9- (sylphamoyl) -5,6,7,8-tetrahydro- [l, 3] dioxol [4,5- g] isoxinolin-5-yl] -CH - isobenzofyran-1-ones 1.3.
  • Example 9 Testing the anticancer activity of compounds of the general formula 1.
  • a focused library of noscapines of the general formula 1 was tested for their ability to suppress cell growth in four tumor lines: DLD-I - colorectal adenocarcinoma; DU-145 - metastatic prostate cancer; T-47D - metastatic breast cancer and Jurkat - T leukemia.
  • cell cultures were maintained in a standard nutrient medium containing specified concentrations of the studied compounds. The substances were introduced into the medium in the form of solutions in DMSO.
  • Profile proliferation of tumor cells was measured using Alamar Blue dye, which allows the number of living cells to be determined photometrically.
  • the invention can be used in medicine, veterinary medicine, biochemistry.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à de nouveaux dérivés substitués de noscapine de formule générale (1) ou à leurs racémates ou isomères optiques ou à leurs sels pharmaceutiquement acceptables et / ou leurs hydrates présentant une activité antitumorale, à la composition pharmaceutique sous la forme de comprimés, de capsules ou d'injections, conditionnés dans un emballage pharmaceutiquement acceptable, ainsi qu'à des procédés de fabrication et à un procédé de suppression de la prolifération qui les mettent en oeuvre. Dans la formule générale (1), R1 est un substitutif de groupe aminé sélectionné parmi un alkyl éventuellement substitué, les substitutifs étant sélectionnés dans un groupe aminé éventuellement substitué, ou un azahétérocycle contenant éventuellement en tant qu'hétéroatome supplémentaire O, S ou N et relié par un atome d'azote au groupe alkylé, éventuellement un aryle substitué, un hétéroaryle ééventuellement substitué et éventuellement condensé contenant un hétéroatome sélectionné parmi l'azote, le soufre et l'oxygène, et d'un sulfamoyle éventuellement substitué. En plus, l'invention concerne 3-(9-iodo-4-métoxy-6-méthyl-5,6,7,8-tétrahydro[1,3]dioxolo-[4,5-g]isoquinoline-5-il)-6,7-dimétoxy-3H- isobenzofuran-1, 3-(9-chlorométhyl-4-métoxy-6-méthyl-5,6,7,8-tétrahydro [1,3]dioxolo-[4,5-g] isoquinoline-5-il)-6,7-dimétoxy-3H-isobenzofuran-1, 5-(4,5-dimétoxy-3-oxo- 1,3-dihydroisonenzofuran-1-il) -4-métoxy-6-méthyl-5,6,7,8-tétrahydro [1,3]dioxolo-[4,5-g] isoquinoline-carbaldéhyde (ou -9-carbonitril, ou -9-sulphonylchlorure, ou acide -9-carboxylique et 3-(9-métoxyméthyl-métoxy-6-méthyl-5,6,7,8-tétrahydro[1,3]dioxolo-[4,5-g]isoquinoline-5-il)-6,7-dimétoxy-3H- isobenzofuran-1 et leurs procédés de fabrication. L'invention porte aussi sur des bibliothèques combinatoire et focalisée.
PCT/RU2007/000138 2006-05-12 2007-03-21 Dérivés de noscapine (et variantes), bibliothèques combinatoire et focalisée, composition pharmaceutique et procédés de fabrication (variantes) et d'utilisation WO2007133112A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006116302 2006-05-12
RU2006116302/04A RU2304584C1 (ru) 2006-05-12 2006-05-12 Производные носкапина (варианты), комбинаторная и фокусированная библиотеки, фармацевтическая композиция, способы их получения (варианты) и применения

Publications (1)

Publication Number Publication Date
WO2007133112A1 true WO2007133112A1 (fr) 2007-11-22

Family

ID=38511911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2007/000138 WO2007133112A1 (fr) 2006-05-12 2007-03-21 Dérivés de noscapine (et variantes), bibliothèques combinatoire et focalisée, composition pharmaceutique et procédés de fabrication (variantes) et d'utilisation

Country Status (2)

Country Link
RU (1) RU2304584C1 (fr)
WO (1) WO2007133112A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028259A2 (fr) * 2008-09-05 2010-03-11 Emory University 9-aminonoscapine et son utilisation dans le traitement des cancers, y compris les cancers résistant aux médicaments
EP2328578A2 (fr) * 2008-09-11 2011-06-08 Emory University Noscapine et analogues de la noscapine et leur utilisation dans le traitement de maladies infectieuses par inhibition par liaison à la tubuline
CN115433195A (zh) * 2021-06-01 2022-12-06 华东理工大学 烷基取代那可丁衍生物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056791A (en) * 1959-10-27 1962-10-02 Sandoz Ag Isoquinoline derivatives
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
US20020137762A1 (en) * 1997-08-19 2002-09-26 Joshi Harish C. Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056791A (en) * 1959-10-27 1962-10-02 Sandoz Ag Isoquinoline derivatives
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
US20020137762A1 (en) * 1997-08-19 2002-09-26 Joshi Harish C. Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028259A2 (fr) * 2008-09-05 2010-03-11 Emory University 9-aminonoscapine et son utilisation dans le traitement des cancers, y compris les cancers résistant aux médicaments
WO2010028259A3 (fr) * 2008-09-05 2010-07-22 Emory University 9-aminonoscapine et son utilisation dans le traitement des cancers, y compris les cancers résistant aux médicaments
US8394957B2 (en) 2008-09-05 2013-03-12 Emory University 9-aminonoscapine and its use in treating cancers, including drug-resistant cancers
US8815835B2 (en) 2008-09-05 2014-08-26 Emory University 9-aminonoscapine and its use in treating cancers, including drug-resistant cancers
EP2328578A2 (fr) * 2008-09-11 2011-06-08 Emory University Noscapine et analogues de la noscapine et leur utilisation dans le traitement de maladies infectieuses par inhibition par liaison à la tubuline
EP2328578A4 (fr) * 2008-09-11 2012-04-25 Univ Emory Noscapine et analogues de la noscapine et leur utilisation dans le traitement de maladies infectieuses par inhibition par liaison à la tubuline
CN115433195A (zh) * 2021-06-01 2022-12-06 华东理工大学 烷基取代那可丁衍生物及其制备方法与应用

Also Published As

Publication number Publication date
RU2304584C1 (ru) 2007-08-20

Similar Documents

Publication Publication Date Title
RU2329044C1 (ru) Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2303597C1 (ru) Фармацевтическая композиция, способы ее получения и применения
EA016234B1 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2008123800A2 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués
WO2007117180A1 (fr) Bibliothèques combinatoire et focalisée d'azahétérocycles, composition pharmaceutique et procédés de leur fabrication
RU2302417C1 (ru) 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека
WO2009010925A2 (fr) Amides azahétérocycliques annelés comprenant un fragment de pyrimidine, procédé de leur fabrication et utilisation
WO2008115098A2 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
WO2008024029A1 (fr) Azépino[4,3-b]indoles substitués, composition pharmaceutique, procédé de fabrication et d'utilisation
US11203597B2 (en) Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
TW202116778A (zh) 作為治療劑之細胞毒素之肽結合物
JP2021501191A (ja) Ｗｅｅ１阻害剤としての大環状化合物及びその使用
JPH0826036B2 (ja) 生理活性物質ｋ−２５２の誘導体
WO2009011617A2 (fr) Azahétérocycles annelés comprenant un fragment de pyrimidine, procédé de leur fabrication et inhibiteurs de pi3k kinases
WO2012163179A1 (fr) Composé d'hexahydrodibenzo[a,g]quinolizine, son procédé de préparation, composition pharmaceutique et son utilisation
WO2007136300A2 (fr) Indoles substitués et procédé de production et d'utilisation de ceux-ci
EP3470404A1 (fr) Dérivé hétérocyclique à cinq éléments, son procédé de production et composition pharmaceutique le comprenant
RU2304584C1 (ru) Производные носкапина (варианты), комбинаторная и фокусированная библиотеки, фармацевтическая композиция, способы их получения (варианты) и применения
RU2629750C2 (ru) НОВЫЕ ДИСПИРО-ИНДОЛИНОНЫ, ИНГИБИТОРЫ MDM2/p53 ВЗАИМОДЕЙСТВИЯ, СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2009093934A2 (fr) 3-sulphonyl-tiène[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines fonctionnant comme des antagonistes des récepteurs 5-ht6 de sérotonine, procédés de fabrication et d'utilisation
WO2009093206A2 (fr) 3-sulfonyl-pyrazolo[1,5-a] pyrimidines fonctionnant comme des antagonistes des récepteurs 5-ht6 de sérotonine, procédés de fabrication et d'utilisation
RU2682678C1 (ru) Способ получения диспироиндолинонов
EP3020719B1 (fr) 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines substituées, antagonistes du récepteur 5-ht6 de sérotonine, procédés de production et d'utilisation associés
WO2007136302A2 (fr) Substances actives, composition pharmaceutique et procédé de fabrication et d'utilisations correspondants
EA022465B1 (ru) ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО[3,2-с]ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07747864

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07747864

Country of ref document: EP

Kind code of ref document: A1